• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS CREATININE PLUS VER.2; ENZYMATIC METHOD, CREATININE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS CREATININE PLUS VER.2; ENZYMATIC METHOD, CREATININE Back to Search Results
Model Number C701
Device Problem Low Test Results (2458)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 11/17/2017
Event Type  malfunction  
Manufacturer Narrative
(b)(4).(b)(6).
 
Event Description
The customer received a questionable low crep2 creatinine plus ver.2 result for one patient.The initial result was 57.5 umol/l from both serum and plasma samples.On a siemens analyzer, the result was 187.23 umol/l from the plasma sample and 190.02 umol/l from the serum sample.On a beckman analyzer, the result was 164 umol/l from the plasma sample and 169 umol/l from the serum sample.The erroneous result was reported outside of the laboratory.There was no allegation of an adverse event.The reagent lot number was 283369.The expiration date was requested but as not provided.
 
Manufacturer Narrative
Additional information was provided that the patient has a gammopathy.Product labeling for the assay documents this interference.As the reaction kinetics for the erroneous results were not available, this interference could not be confirmed to be the root cause.
 
Manufacturer Narrative
Two samples (serum and plasma) were received for investigation and tested on a cobas 8000 c 702 module for both crej2 creatinine jaffé gen.2 and crep2 creatinine plus ver.2.The creatinine results for both samples and both methods were similar.Based on these results, the customer results were confirmed.All results for igg were within the normal range, the results for iga were slightly above the reference range, and the result of igm was increased.Due to the high concentration of immunoglobulin, possible igm interference exists.The investigation was unable to find a definitive root cause.As calibration and qc results were acceptable, a general reagent issue could be excluded.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CREATININE PLUS VER.2
Type of Device
ENZYMATIC METHOD, CREATININE
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
Manufacturer (Section G)
ROCHE DIAGNOSTICS GMBH
sandhoferstrasse 116
na
mannheim (baden-wurttemberg) 68305
GM   68305
Manufacturer Contact
michael leslie
9115 hague road
na
indianapolis, IN 46250
3175214343
MDR Report Key7086082
MDR Text Key95071163
Report Number1823260-2017-02852
Device Sequence Number1
Product Code JFY
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
K024098
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Reporter Occupation Health Professional
Type of Report Initial,Followup,Followup
Report Date 02/16/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/06/2017
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberC701
Device Catalogue Number05168589190
Device Lot Number283369
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? Yes
Date Manufacturer Received11/21/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage N
Patient Sequence Number1
-
-